BiotechTube

Adalimumab

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Jan 14, 2020 → May 1, 2028

NCT ID
NCT04183608

About Adalimumab

Adalimumab is a approved stage product being developed by AbbVie for Ulcerative Colitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04183608. Target conditions include Ulcerative Colitis.

What happened to similar drugs?

14 of 20 similar drugs in Ulcerative Colitis were approved

Approved (14) Terminated (5) Active (6)
✅Azathioprine + PlaceboCelltrionApproved
✅Filgotinib MaleateEisaiApproved
✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved
✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved
✅GolimumabMerckApproved
✅GolimumabMerckApproved
✅Prefilled Syringe delivery of Golimumab + Smartject Device delivery of GolimumabMerckApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT05414201ApprovedCompleted
NCT04183608ApprovedRecruiting
NCT03311464Phase 3Completed
NCT03261102Pre-clinicalActive
NCT02897115ApprovedTerminated
NCT02904902Phase 3Completed
NCT02668640Pre-clinicalCompleted
NCT02750800Pre-clinicalCompleted
NCT02739828Pre-clinicalCompleted
NCT02634541ApprovedUNKNOWN
NCT02632175Phase 3Completed
NCT02533375Phase 3Completed
NCT02499783Phase 3Completed
NCT02198651ApprovedCompleted
NCT02333383Pre-clinicalCompleted
NCT02539849Pre-clinicalCompleted
NCT02185014Phase 3Completed
NCT02148718ApprovedCompleted
NCT02065622Phase 3Completed
NCT02016482Phase 3Completed

Competing Products

20 competing products in Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
40
MirikizumabEli LillyPhase 2
35
Azathioprine + PlaceboCelltrionApproved
35
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
TacrolimusAstellas PharmaPhase 3
40
tacrolimus + PlaceboAstellas PharmaPhase 3
40
Filgotinib MaleateEisaiApproved
50
AJM300 + PlaceboEisaiPhase 3
40
GSK3050002 + PlaceboEisaiPhase 1
29
adalimumab + placeboEisaiPhase 3
40
E6007 + PlaceboEisaiPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 1
29
Arm1 + Arm 2Zydus LifesciencesPhase 2
35
Mirikizumab + MirikizumabEli LillyPhase 3
44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 2
27
Mirikizumab + PlaceboEli LillyPhase 2
35
LY4268989 + PlaceboEli LillyPhase 2
42